Drugs / SIIL LAIV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01625689 | Jun 2012 → Feb 2013 | influenza | PATH Vaccine Solutions | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIIL LAIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01625689 ↗ |
| Modality | Vaccine | “The experimental intervention is Serum Institute of India Ltd's Trivalent, Seasonal Live Attenuated Influenza Vaccine (SIIL LAIV).” NCT01625689 ↗ |
| Route | Intranasal | “The SIIL LAIV is administered in a 0.5 ml intranasal dose” NCT01625689 ↗ |